Maria Teresa Esposito Author

Research Article Subscription

Trastuzumab Resistance: What Are We Offering to Breast Cancer Patients?

Author(s):

Sonel Patel, Nandini Hayes and Maria Teresa Esposito

Human epidermal growth factor receptor-2 (HER2/ErbB-2) is a receptor tyrosine kinase involved in cell growth and differentiation and over-expressed in about 15-30% of breast cancers. Trastuzumab is an anti-HER2 monoclonal antibody that has significantly improved survival of patients with early and metastatic breast cancer (BC). However, 65% patients experience primary and secondary resistance. This article explores existing and emerging combination therapy for HER2 positive breast cancer, highlighting the success of trastuzumab in combination with another monoclonal antibody, pertuzumab and small molecule tyrosine kinase inhibitors lapatinib and neratinib. Recent studies have indicated that combination of trastuzumab, pertuzumab and lapatinib increases the 3-year overall survival from 9... view more»

DOI: 10.4172/2324-9110.1000203

Abstract HTML PDF